4-P-PDOT
Based on 13 publication(s) in Google Scholar
4-P-PDOT is a potent, selective and affinity Melatonin receptor (MT2) antagonist. 4-P-PDOT is >300-fold more selective for MT2 than MT1. 4-P-PDOT significantly counteracts Melatonin-mediated antioxidant effects (GSH/GSSG ratio, phospho-ERK, Nrf2 nuclear translocation, Nrf2 DNA-binding activity).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.90%
- No. CAS: 134865-74-0
- Fòrmula: C19H21NO
- Peso molecular:279.38
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
NF-κB Signaling Compound Library
HY-L014
-
Antioxidant Compound Library
HY-L037
-
Targeted Diversity Library
HY-L099
-
Human Metabolite Library
HY-L123
-
Cuproptosis Compound Library
HY-L133
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) 4-P-PDOT
More- Autophagy. 2026 Jun 25:1-16. [Abstract]
- J Adv Res. 2026 Apr 13:S2090-1232(26)00337-1. [Abstract]
- Immun Ageing. 2024 Sep 5;21(1):59. [Abstract]
- J Pineal Res. 2026 Mar;78(2):e70139. [Abstract]
- J Pineal Res. 2026 Mar;78(2):e70135. [Abstract]
- J Pineal Res. 2024 Sep;76(6):e13006. [Abstract]
- Eur J Pharmacol. 2021 Dec 5:912:174589. [Abstract]
- Cell Oncol (Dordr). 2026 Jun 23. [Abstract]
- Int J Mol Sci. 2024 Jan 5;25(2):733. [Abstract]
- Zool Res. 2022 Jul 18;43(4):537-551. [Abstract]
- Tissue Cell. 2025 Sep 6:98:103131. [Abstract]
- bioRxiv. 2023 Apr 19.
- Oxid Med Cell Longev. 2021 Jun 23:2021:9981480. [Abstract]
Actividad biológica
|
MT2 |
In CHO-mt1 cells the amidotetraline 4-P-PDOT (10 mM) has no effect on forskolin-stimulated cyclic AMP levels, either alone, or in the presence of Melatonin. In contrast, in CHO-MT2 cells, 4-P-PDOT is an agonist, producing a concentration-dependent inhibition of forskolin stimulated cyclic AMP, with a pEC50 value of 8.72 and intrinsic activity of 0.86[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HT-29 and HeLa cells.
-
Concentration:50 µM
-
Incubation Time:30 min
-
Result:Produced a negligible effect on cell viability induced by melatonin.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Klotho mutant mice treatment with Melatonin[2]
-
Dosage:0.5 mg/kg or 1.0 mg/kg
-
Administration:Intravenous injection
-
Result:Significantly reversed antioxidant effects mediated by Melatonin. Significantly reversed the changes in the levels of these GSH-related parameters. Significantly reversed the memory function of Melatonin-treated klotho mutant mice.
Chemical Information
-
No. CAS 134865-74-0
-
Appearance Solid
-
Peso molecular 279.38
-
Fòrmula C19H21NO
-
Color Off-white to yellow
-
SMILES
CCC(NC1CC2=C(C=CC=C2)C(C3=CC=CC=C3)C1)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
2026 Jun 25:1-16. PMID: 42290138 -
J Adv Res
Portulaca oleracea L. polysaccharide alleviates colitis-associated bone loss through Muribaculaceae-enriched gut microbiota and elevated colonic melatonin. [Abstract]2026 Apr 13:S2090-1232(26)00337-1. PMID: 41980626 -
Immun Ageing
Melatonin enhances NK cell function in aged mice by increasing T-bet expression via the JAK3-STAT5 signaling pathway. [Abstract]2024 Sep 5;21(1):59. PMID: 39237911 -
J Pineal Res
Melatonin Promotes the Synthesis and Secretion of Growth Hormone in the Adenohypophysis by Activating the cAMP/FOXO1 Pathway. [Abstract]2026 Mar;78(2):e70139. PMID: 41870323 -
J Pineal Res
Melatonin Enhances the Myometrial Contraction Through MT2-PKC-NRF2/MAFF Signaling Pathway in Sows. [Abstract]2026 Mar;78(2):e70135. PMID: 41854048 -
J Pineal Res
Melatonin Regulates Neuronal Synaptic Plasticity in the Supramammillary Nucleus and Attenuates Methamphetamine-Induced Conditioned Place Preference and Sensitization in Mice. [Abstract]2024 Sep;76(6):e13006. PMID: 39221552 -
Eur J Pharmacol
Anticonvulsant activity of melatonin and its success in ameliorating epileptic comorbidity-like symptoms in zebrafish. [Abstract]2021 Dec 5:912:174589. PMID: 34699755 -
Cell Oncol (Dordr)
Tasimelteon inhibits glioma proliferation by inducing ferroptosis via the SP1/ACSL4 pathway. [Abstract]2026 Jun 23. PMID: 42334777 -
Int J Mol Sci
Melatonin Alleviates Lipopolysaccharide-Induced Abnormal Pregnancy through MTNR1B Regulation of m6A. [Abstract]2024 Jan 5;25(2):733. PMID: 38255808 -
Zool Res
Production of functional sperm from in vitro-cultured premeiotic spermatogonia in a marine fish. [Abstract]2022 Jul 18;43(4):537-551. PMID: 35616259 -
Tissue Cell
Melatonin alleviates cholestatic liver injury through modulating gut microbiota and activating the NRF2/HO-1 antioxidant pathway. [Abstract]2025 Sep 6:98:103131. PMID: 40925262 -
-
Oxid Med Cell Longev
Melatonin Ameliorates Corticosterone-Mediated Oxidative Stress-Induced Colitis in Sleep-Deprived Mice Involving Gut Microbiota. [Abstract]2021 Jun 23:2021:9981480. PMID: 34257825
Solvente y solubilidad
DMSO : 41.67 mg/mL (149.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 4.17 mg/mL (14.93 mM); Clear solution
This protocol yields a clear solution of ≥ 4.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (41.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Dubocovich ML. Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci. 1995 Feb;16(2):50-6. [Content Brief]
[2]. hin EJ, et al. Melatonin attenuates memory impairment induced by Klotho gene deficiency via interactive signaling between MT2 receptor, ERK, and Nrf2-related antioxidant potential. Int J Neuropsychopharmacol. 2014 Dec 30;18(6). pii: pyu105. [Content Brief]
[4]. Dubocovich ML, et al. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):365-75. [Content Brief]
[5]. Roberto Pariente, et al. Participation of MT3 melatonin receptors in the synergistic effect of melatonin on cytotoxic and apoptotic actions evoked by chemotherapeutics. Cancer Chemother Pharmacol. 2017 Nov;80(5):985-998. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5794 mL | 17.8968 mL | 35.7935 mL | 89.4839 mL |
| 5 mM | 0.7159 mL | 3.5794 mL | 7.1587 mL | 17.8968 mL | |
| 10 mM | 0.3579 mL | 1.7897 mL | 3.5794 mL | 8.9484 mL | |
| 15 mM | 0.2386 mL | 1.1931 mL | 2.3862 mL | 5.9656 mL | |
| 20 mM | 0.1790 mL | 0.8948 mL | 1.7897 mL | 4.4742 mL | |
| 25 mM | 0.1432 mL | 0.7159 mL | 1.4317 mL | 3.5794 mL | |
| 30 mM | 0.1193 mL | 0.5966 mL | 1.1931 mL | 2.9828 mL | |
| 40 mM | 0.0895 mL | 0.4474 mL | 0.8948 mL | 2.2371 mL | |
| 50 mM | 0.0716 mL | 0.3579 mL | 0.7159 mL | 1.7897 mL | |
| 60 mM | 0.0597 mL | 0.2983 mL | 0.5966 mL | 1.4914 mL | |
| 80 mM | 0.0447 mL | 0.2237 mL | 0.4474 mL | 1.1185 mL | |
| 100 mM | 0.0358 mL | 0.1790 mL | 0.3579 mL | 0.8948 mL |
4-P-PDOT Related Classifications
HY-100609 Related Classifications
Powered by Bioz